Genvor's Losses Mount Amid Zero Revenue, Cash Dwindles to $641

TL;DR

**Genvor is burning cash at an alarming rate with no revenue, making it a highly speculative bet on future tech breakthroughs.**

AI Summary

Genvor Inc. (GNVR) reported no revenue for the three and six months ended March 31, 2025, continuing its pre-commercialization phase. The company posted a net loss of $5,300,234 for the six months ended March 31, 2025, a significant increase from the $2,123,482 net loss in the prior year period. Operating expenses surged to $5,273,470 for the six months, primarily driven by a substantial increase in compensation and related benefits to $5,098,594 from $931,465 in the comparable period. Genvor's cash position remains critically low at $641 as of March 31, 2025, and it has a working capital deficit of $2,089,850. The company is developing plant-based defense technology using its BioCypher Algorithm, an AI-driven peptide discovery platform, and has achieved technical formulation advancements for its antimicrobial peptide platform, with lead candidate GV185 showing strong antifungal activity. Despite these developments, the company's limited operational history and lack of revenue raise substantial doubt about its ability to continue as a going concern, relying on future capital raises and strategic partnerships.

Why It Matters

Genvor's 10-Q filing reveals a company in a precarious financial state, with zero revenue and a rapidly expanding net loss of $5.3 million for the six months ended March 31, 2025. This signals high risk for investors, as the company's ability to fund its innovative plant-based defense technology development is severely constrained by a mere $641 in cash. For employees, the going concern warning could indicate job insecurity. In the competitive agricultural biotech market, Genvor's reliance on future capital raises and licensing deals, despite promising peptide technology, puts it at a disadvantage against better-capitalized rivals, potentially impacting its ability to bring solutions to farmers and the broader market.

Risk Assessment

Risk Level: high — Genvor's risk level is high due to its critical liquidity issues, evidenced by a cash balance of only $641 and a working capital deficit of $2,089,850 as of March 31, 2025. The company also reported a net loss of $5,300,234 for the six months ended March 31, 2025, with no revenues, leading management to explicitly state 'substantial doubt about the Company's ability to continue as a going concern.'

Analyst Insight

Investors should exercise extreme caution and avoid Genvor Inc. (GNVR) given its severe liquidity issues, lack of revenue, and explicit going concern warning. Potential investors should wait for clear evidence of successful commercialization, significant revenue generation, and a strengthened balance sheet before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$21,041

total Debt

$2,097,905

net Income

-$5,300,234

eps

N/A

gross Margin

N/A

cash Position

$641

revenue Growth

N/A

Key Numbers

• $0 — Revenue (for the three and six months ended March 31, 2025, indicating pre-commercialization)
• $5,300,234 — Net Loss (for the six months ended March 31, 2025, a significant increase from $2,123,482 in the prior year)
• $641 — Cash (as of March 31, 2025, highlighting severe liquidity issues)
• $2,089,850 — Working Capital Deficit (as of March 31, 2025, indicating inability to meet short-term obligations)
• $25,904,499 — Accumulated Deficit (as of March 31, 2025, reflecting significant historical losses)
• $5,098,594 — Compensation and Related Benefits (for the six months ended March 31, 2025, a substantial increase from $931,465 in the prior year)
• 29,825,763 — Common Stock Shares Outstanding (as of September 08, 2025)
• 72% — Reduction in fungal growth (demonstrated by transgenic corn peptide AGM182 in USDA trials)
• 98% — Reduction in aflatoxin (demonstrated by transgenic corn peptide AGM182 in USDA trials)

Key Players & Entities

• Genvor Inc. (company) — registrant
• GNVR (company) — ticker symbol
• SEC (regulator) — Securities and Exchange Commission
• BioCypher Algorithm (company) — proprietary AI-driven peptide discovery platform
• Nexion Biosciences LLC (company) — wholly owned subsidiary of Old Genvor
• GV185 (company) — lead antimicrobial peptide candidate
• USDA (regulator) — United States Department of Agriculture
• Allure Worldwide, Inc. (company) — former name of Genvor Incorporated
• Old Genvor (company) — accounting acquirer in reverse merger

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: Genvor Inc. has a critically low cash position of $641 as of March 31, 2025, and a working capital deficit of $2,089,850. This indicates a significant inability to meet short-term obligations and raises substantial doubt about the company's ability to continue as a going concern.
• Increasing Net Losses [high — financial]: The company reported a net loss of $5,300,234 for the six months ended March 31, 2025, a substantial increase from $2,123,482 in the prior year period. This trend, coupled with zero revenue, highlights ongoing financial challenges.
• Pre-Commercialization Phase [high — operational]: Genvor Inc. has no revenue for the three and six months ended March 31, 2025, as it remains in a pre-commercialization phase. The company's success is contingent on future product development, regulatory approvals, and market adoption.
• Surging Operating Expenses [medium — operational]: Operating expenses for the six months ended March 31, 2025, surged to $5,273,470, primarily driven by a significant increase in compensation and related benefits to $5,098,594 from $931,465 in the prior year. This rapid escalation in costs requires careful management.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $25,904,499 as of March 31, 2025, reflecting substantial historical losses. This indicates a long-standing challenge in achieving profitability.
• Reliance on Future Capital Raises [high — financial]: The company's ability to continue operations is heavily dependent on its capacity to secure future capital raises and strategic partnerships. The extremely low cash balance of $641 underscores this immediate need.

Industry Context

Genvor Inc. operates in the agricultural technology sector, focusing on developing sustainable solutions through AI-driven peptide discovery. The industry is characterized by a growing demand for yield enhancement, stress tolerance, and reduced chemical inputs. Key players are investing heavily in R&D for novel crop protection and performance enhancement technologies, with a trend towards biological solutions and precision agriculture.

Regulatory Implications

As a developer of agricultural technologies, Genvor Inc. will face significant regulatory scrutiny regarding product safety, efficacy, and environmental impact. Obtaining approvals from bodies like the EPA (in the US) and equivalent international agencies will be critical for market entry and commercialization, requiring substantial investment in testing and compliance.

What Investors Should Do

1. Monitor future capital raises closely.
2. Evaluate the progress of strategic partnerships.
3. Assess the timeline and milestones for product commercialization.
4. Analyze the sustainability of the current operating expense structure.

Key Dates

• 2025-03-31: End of Second Quarter — Reported $0 revenue, a net loss of $5,300,234 for the six months, and a cash balance of $641, highlighting severe liquidity issues and continued pre-commercialization status.
• 2024-09-30: End of Fiscal Year — Previous balance sheet date, showing a cash position of $373 and a total assets of $35,580.

Glossary

BioCypher Algorithm

An AI-driven peptide discovery platform used by Genvor Inc. to accelerate the identification and validation of peptide solutions for agricultural applications. (This is the core proprietary technology Genvor leverages for its product development and competitive advantage.)

Pre-commercialization phase

A stage in a company's lifecycle where it is developing products or services but has not yet begun generating revenue from sales. (Genvor Inc. is in this phase, meaning its financial performance is characterized by expenses without corresponding revenue, and its future success depends on market entry.)

Working Capital Deficit

A situation where a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term financial obligations. (Genvor Inc. has a significant working capital deficit of $2,089,850, signaling immediate financial strain.)

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income. (Genvor Inc.'s accumulated deficit of $25,904,499 indicates a history of significant losses.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future, without the intention or need for liquidation. (The company's financial situation raises substantial doubt about its ability to continue as a going concern.)

Year-Over-Year Comparison

Compared to the prior year period, Genvor Inc. shows a stark deterioration in its financial standing. While revenue remains at $0, the net loss has more than doubled, reaching $5,300,234 for the six months ended March 31, 2025, compared to $2,123,482 in the prior year. This increased loss is largely attributable to a significant surge in operating expenses, particularly compensation and related benefits, which jumped from $931,465 to $5,098,594. The cash position has also declined, albeit from an already critically low level, and the working capital deficit has widened, underscoring the heightened financial pressure.

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common Stock, $0.001 par value (Title of class) Indicate
• $641 — March 31, 2025, the Company had cash of $641. The accompanying condensed consolida
• $2,089,850 — ompany had a working capital deficit of $2,089,850. At March 31, 2025, the Company had an
• $25,904,499 — e Company had an accumulated deficit of $25,904,499. For the six months ended March 31, 202
• $5,300,234 — 5, the Company recognized a net loss of $5,300,234 and used cash in operating activities o
• $72,575 — nd used cash in operating activities of $72,575, with no revenues earned, and limited o

Filing Documents

• gnvr_10q.htm (10-Q) — 719KB
• ex31_1.htm (EX-31.1) — 13KB
• ex31_2.htm (EX-31.2) — 13KB
• ex32_1.htm (EX-32.1) — 6KB
• ex32_2.htm (EX-32.2) — 6KB
• image_001.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 202KB
• 0001903596-25-000455.txt ( ) — 4279KB
• gnvr-20250331.xsd (EX-101.SCH) — 25KB
• gnvr-20250331_cal.xml (EX-101.CAL) — 31KB
• gnvr-20250331_def.xml (EX-101.DEF) — 139KB
• gnvr-20250331_lab.xml (EX-101.LAB) — 254KB
• gnvr-20250331_pre.xml (EX-101.PRE) — 223KB
• gnvr_10q_htm.xml (XML) — 499KB

OTHER

PART II. OTHER INFORMATION Item 1. Legal Proceedings 12 Item 1A. Risk Factors 12 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12 Item 3. Defaults Upon Senior Securities 12 Item 4. Mine Safety Disclosures 12 Item 5. Other Information 12 Item 6. Exhibits 13

SIGNATURES

SIGNATURES 14 PART I – FINANCIAL INFORMATION

Financial

Item 1. Financial Genvor Incorporated Index to Financial Page Condensed Consolidated Balance Sheets at March 31, 2025 (unaudited), and September 30, 2024 F-1 Condensed Consolidated Statements of Operations for the three and six months ended March 31, 2025, and 2024 (unaudited) F-2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended March 31, 2025, and 2024 (unaudited) F-3 Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2025, and 2024 (unaudited) F-4 Notes to Condensed Consolidated Financial Statements (unaudited) F-5 Genvor Incorporated Condensed Consolidated Balance Sheets March 31, September 30, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 641 $ 373 Prepaid expense 7,414 21,305 Total Current Assets 8,055 21,678 NON-CURRENT ASSETS: Property and equipment, net 12,986 13,902 Total Non-current Assets 12,986 13,902 Total Assets $ 21,041 $ 35,580 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Convertible note payable, net $ 14,074 $ 7,408 Notes payable 897,000 897,000 Accrued interest 29,865 9,822 Accounts payable and accrued expenses 321,385 303,264 Accrued compensation and related expenses 696,926 466,404 Advances from related parties 89,905 17,062 SBA loan 48,750 48,750 Total Current Liabilities 2,097,905 1,749,710 Total Liabilities 2,097,905 1,749,710 Commitments and Contingencies (Note 6) — — STOCKHOLDERS' DEFICIT: Preferred stock, $ 0.001 par value; 20,000,000 shares authorized; Series A Preferred Stock, 10 shares authorized; 6 shares issued and outstanding at March 31, 2025 and September 30, 2024 — — Series B Preferred Stock, 2,500,000 shares authorized; 2,060,536 shares issued and 1,558,024 shares outstanding at March 31, 2025 and September 30, 2024 2,061 2,061 Common stock, $ 0.001 par value; 300,000,000 shares a

Business

Business Plan and Strategy Genvor's business strategy centers on leveraging its proprietary BioCypher Algorithm, an AI-driven peptide discovery platform, to create sustainable agricultural solutions that optimize crop performance across diverse growing conditions. The Company's peptide technologies are designed to enhance yields, improve stress tolerance, and deliver nutrient optimization while addressing critical agricultural challenges including plant diseases, toxins, bacteria, and fungi. These innovations are designed to support farmers and growers worldwide by improving agricultural productivity, reducing chemical inputs, and enhancing economic outcomes through residue-free solutions that meet evolving regulatory requirements and consumer demands. F-6 The Company is advancing its portfolio of engineered peptide technologies through its proprietary BioCypher Algorithm, which accelerates the discovery and validation of commercial-grade peptide solutions. Genvor's platform supports multiple formulation approaches including foliar applications, transgenic seed traits, and seed treatment delivery systems, creating cross-crop scalability opportunities in row crops and specialty crops. The Company is leveraging its extensive peptide library of 50,000+ designed peptides to address high-value agricultural performance applications including yield enhancement, stress tolerance, nutrient use efficiency, and biological crop protection, as well as adjacent opportunities in animal health and feed optimization. Notable validation includes the Company's transgenic corn peptide AGM182, which demonstrated 72% reduction in fungal growth and 98% reduction in aflatoxin in USDA trials. Genvor's commercial model employs a licensing-first strategy centered on forming strategic partnerships, joint development agreements (JDAs), and licensing arrangements that create mutual competitive advantages. The Company's approach enables agricultural leaders to access validated peptide tech

View Full Filing

View this 10-Q filing on SEC EDGAR